Warren Buffett’s bid for Unilever plc: the 3 simple truths for investors like you

Warren Buffett’s bid for Unilever plc (LON:ULVR) might have highlighted its hidden value – even at a historically high share price

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many observers were appalled by the 2010 takeover of iconic British confectionery company Cadbury by America’s Kraft Foods, angry at its aftermath of broken promises and job losses.
 
Shareholders, though, could be forgiven for being more sanguine – and indeed, many happily sold their shares, seeing in Kraft’s offer a way of unlocking more value from their investment than Cadbury’s own management had been able to achieve.

And that Warren Buffett and Brazilian billionaire Jorge Lemann subsequently combined forces to buy Kraft in 2015 (by now divested of its snack and confectionary businesses, including Cadbury’s) is one of life’s richer ironies: now it was American factories closing, as Lemann’s fabled cost-cutting tactics got to work.

Déjà vu, all over again

Such thoughts probably went through many people’s minds on February 17th, when Kraft – now joined with Buffett’s HJ Heinz as Kraft-Heinz – submitted a bid for Unilever (LSE: ULVR), promptly sending the shares soaring 14%.
 
Like Cadbury, Unilever seems to be a company for which people have something of a soft spot. In part, that’s thanks to its array of trusted brands, stretching from foodstuffs such as Flora, Lipton’s, Knorr, Hellman’s, Wall’s, and – of course – Marmite and Bovril, to personal care and cleaning products such as Sunsilk, Persil, Dove, and Timotei.
 
Not withstanding that, its environmental and sustainability initiatives have also won the firm plaudits, even from green and consumer activists generally ill-disposed to the business world.
 
And on a personal note, my own interactions over the years with Unilever people and factories have been unfailingly impressive, in part prompting me to make the company one of my larger shareholdings.

Heady returns

As we all now know, the Kraft-Heinz bid collapsed after a few days, as it became clear that Unilever management would robustly defend their business, its heritage and its values. And has now also become apparent, it helped that they had muscular support from politicians and large investors.
 
But the 14% premium that the bid added to Unilever’s share price has remained – and even increased, after Unilever’s chief executive, Paul Polman, stated that the company would look for ways to accelerate returns for investors.
 
Not to put too fine a point on it, Unilever shares are at an all-time high, up 176% over ten years – a period over which the FTSE 100 has risen only 13%. Who said that consumer goods businesses were staid and boring?
 
In other words, it’s a situation very much like the proposed Pfizer takeover bid for pharmaceuticals giant AstraZeneca in early 2014. Although that too collapsed, it bid up AstraZeneca’s share price to lofty levels that remained long after Pfizer had walked away.
 
In short, for investors, it’s very much a ‘heads I win, tails I also win’ situation: there was a handsome reward for holding AstraZeneca and Unilever shares, irrespective of whether the bid succeeded or not.

Valuing value

That a canny operator like Warren Buffett should see hidden value in Unilever is not surprising.

Very largely, it’s what he has built his career on, having famously learned his trade from master investor Benjamin Graham, whose book The Intelligent Investor remains a classic to this day. (Buffett, incidentally, wrote both the preface and the appendix of the 2003 edition, updated by Jason Zweig – himself no investing slouch.)
 
Because seeing – and unlocking – hidden value is what all investors should aspire to, looking for companies where the prevailing market price fails to fully reflect the business’s growth or earnings prospects.
 
It’s what I do, it’s what the analysts at the Motley Fool Share Advisor service do, and – if you invest – it’s what you do, too.

Simple truths

So what are the lessons to learn from all this? There are three, I think.
 
One: the link between value and price isn’t as strong as you might think. Up until Buffett’s bid, most people would have thought Unilever expensive.
 
Two: potential value is one thing, unlocked value quite another. If you – like me – hold Unilever and AstraZeneca, then we have predators to thank for our gains.

And three: in companies, as with investing in general, slow-and-steady value-building wins plaudits, and earns trust. Unlike Cadbury, Unilever and AstraZeneca won out because investors thought that their future was better than their past.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Malcolm owns shares in Unilever and AstraZeneca.  The Motley Fool owns shares in Unilever and has recommended shares in AstraZeneca.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »